Oral Gemifloxacin Versus Intravenous Cefotaxime in Treatment of Spontaneous Bacterial Peritonitis

Phase 3

Recruiting

• Conditions: Spontaneous Bacterial Peritonitis
• Interventions: Drug: Gemifloxacin; Drug: Cefotaxime

• Registration Number: NCT04168099
• Lead Sponsor: Tanta University

Brief Summary

oral Gemifloxacin versus intravenous Cefotaxime in treatment of spontaneous bacterial peritonitis

Detailed Description

Comparative Study between the Efficacy of oral Gemifloxacin and intravenous Cefotaxime in treatment of spontaneous bacterial peritonitis

Study Timeline

• Study Start: 2018-12-01
• Status Verified: 2019-11
• Study First Submitted: 2019-11-15
• Study First Submitted QC: 2019-11-15
• Last Update Submitted: 2019-11-15
• Study First Posted: 2019-11-19
• Last Update Posted: 2019-11-19
• Primary Completion: 2028-12-01
• Study Completion: 2028-12-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Patients with spontaneous bacterial peritonitis

Exclusion Criteria

• secondary peritonitis

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Gemifloxacin	Gemifloxacin	Oral Gemifloxacin
Cefotaxime	Cefotaxime	Cefotaxime intravenous

Primary Outcome Measures

Name	Time	Method
Number of patients with resolution of infection	6 months	the total number of patients with resolution of infection

Trial Locations

Locations (1)

Sherief Abd-Elsalam; 🇪🇬 Tanta, Egypt